TriSalus Life Sciences® Inc. , is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary Unaudited Fourth Quarter ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...